-
Recombinant Mouse SHH in Comparative Morphogenesis
2026-09-11
Discover how Recombinant Mouse Sonic Hedgehog and the P1230 SHH protein can turn comparative embryology into a causal, stage-aware assay strategy. This guide connects product biology with evidence from mouse–guinea pig genital development and practical experimental design.
-
T-5224: Mapping AP-1 in Inflammation Assays
2026-09-11
T-5224 is a selective C-Fos/AP-1 inhibitor for dissecting inflammatory and osteoclastogenic transcription. This article explains how to use it as a causal assay perturbation, including a carefully bounded comparison with microbial extracellular-vesicle signaling in cancer research.
-
Moesin as a Biomarker of Endothelial Injury in Sepsis
2026-09-10
The reference study identifies circulating moesin as a candidate indicator of endothelial injury and sepsis severity, linking higher serum levels with SOFA scores, procalcitonin, pulmonary permeability, and lung damage. By combining patient samples, LPS and cecal ligation and puncture models, and endothelial-cell silencing experiments, the work also implicates the ROCK1/MLC and NF-κB pathways in moesin-associated barrier dysfunction.
-
Talin1–Piezo1–YAP Axis in Atherosclerosis
2026-09-10
A 2026 study identifies Talin1 as a mechanistic link between Piezo1-dependent calcium influx, YAP activity, and inflammatory endothelial behavior under atherosclerosis-associated stress. By combining an ApoE-knockout mouse model with TNF-α and oscillatory-shear-stress experiments in endothelial cells, the work positions Talin1 as a potential target for more selective vascular anti-inflammatory strategies.
-
Intestinal TM6SF2 and the Gut–Liver Axis in MASH
2026-09-09
A 2025 Nature Metabolism study identifies intestinal TM6SF2 as a protective regulator of the gut–liver axis, linking epithelial lipid handling to barrier integrity, microbial composition and hepatic lysophosphatidic acid signaling. Its conditional knockout, fecal-transfer, co-housing and pharmacological experiments provide a mechanistic framework for understanding how intestinal dysfunction can initiate MASH beyond the liver itself.
-
Cisplatin Workflows for Cancer Research
2026-09-09
Build more informative CDDP experiments by connecting DNA damage, apoptosis, oxidative stress, and chemotherapy resistance readouts in one workflow. Extend conventional viability testing into macrophage–tumor studies and tumor growth inhibition in xenograft models with practical handling and troubleshooting guidance.
-
Pregnenolone Carbonitrile: PXR Workflow Guide
2026-09-08
Pregnenolone Carbonitrile is a practical rodent PXR agonist for connecting cytochrome P450 CYP3A induction with hepatic detoxification and liver fibrosis assays. This workflow also translates a recent PXR–AVP discovery into controlled water-homeostasis experiments while separating established applications from emerging biology.
-
FITC Goat Anti-Rabbit IgG (H+L) Antibody for HMGB1
2026-09-08
Learn how the FITC Goat Anti-Rabbit IgG (H+L) Antibody supports fluorescent validation of HMGB1 and other rabbit-primary-antibody assays. This guide connects quantitative proteomic discovery with practical immunofluorescence, flow cytometry, and tissue-detection decisions.
-
2-D08: Selective Sumoylation Workflow
2026-09-07
2-D08 enables mechanistic studies of substrate-transfer blockade without directly suppressing E1 activation or Ubc9–SUMO thioester formation. This workflow shows how to apply it to topoisomerase I assays, cancer cell line sumoylation studies, and hypothesis-driven analysis of the SUMO1–FUNDC1 mitophagy pathway.
-
ATG9A, PTOV1, and 14-3-3 Cancer Mechanisms
2026-09-05
The reference study identifies ATG9A and PTOV1 as previously unrecognized 14-3-3 interaction partners and defines distinct mechanisms linking them to autophagy, protein stability, and oncogenic signaling. Its combination of proximity labeling, quantitative proteomics, and biochemical validation provides a framework for studying how phosphorylation-dependent protein interactions regulate cancer-relevant cell biology.
-
EDC.HCl Technical Coupling Guide
2026-09-05
EDC.HCl is a water-soluble carbodiimide used to activate carboxyl groups for in vitro amide bond formation with primary amines. This guide covers practical preparation, controls, storage, and troubleshooting for peptide synthesis and bioconjugation, while noting that no in vivo or clinical data are available for this product.
-
Separating Growth Arrest from Cell Death in Cancer
2026-09-04
Hannah R. Schwartz’s dissertation distinguishes relative viability from fractional viability, showing that these measures capture different components of an anticancer response. The framework supports more informative time-course experiments by separating proliferative arrest from actual cell killing rather than treating a single viability endpoint as a complete pharmacologic description.
-
SB 431542 in Myogenic Progenitor Assays
2026-09-04
SB 431542 is an ALK5 inhibitor that can turn TGF-β signaling into a testable variable in human myogenic progenitor studies. This article connects receptor-proximal pharmacology with long-term engraftment, satellite-cell formation, and assay interpretation without assuming that pathway blockade alone proves regenerative benefit.
-
EZ Cap™ mCherry mRNA: Reliable Red Reporter
2026-09-03
Learn how mCherry mRNA can separate transfection performance from true cytotoxicity in cell-based assays. This scenario-driven guide explains how SKU R1017, EZ Cap™ mCherry mRNA (5mCTP, ψUTP), supports controlled fluorescent protein expression through defined capping, modified nucleotides, and poly(A) design.
-
GTP Solution (100 mM) for mRNA Assay Rigor
2026-09-03
GTP Solution is more than an in vitro transcription input: its concentration, pH, nuclease status, and storage history can shape the interpretation of downstream mRNA and LNP experiments. This evidence-led guide connects nucleotide quality control with the localized p21 mRNA–LNP bladder cancer study.